Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06651593
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SAR444881 — DRUG
    Given by IV
  • Cemiplimab — DRUG
    Given by Iv

Study Details

To study possible biomarkers that may be related to how SAR444881 works (either alone or when combined with cemiplimab) in participants with solid tumors.

Key Dates

Start date
Jul 2, 2025
Status verified
May 2026
Primary completion
Sep 1, 2028
Completion
Sep 1, 2030

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment with SAR444881 and Cemiplimab
    SAR444881 will be given by vein over about 60 minutes on Day 1 of each cycle. Cemiplimab will be administered by vein over about 30 minutes on Day 1 of each cycle, starting with Cycle 2. During Cycle 1, you will only receive SAR444881. Starting on Day 1 of Cycle 2 and for all other cycles, you will receive both SAR444881 and cemiplimab.

Primary Outcome Measure

Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Md Anderson Cancer CenterHoustonTexas77030
Aung Naing, md
[email protected]
713-563-3885
Aung Naing, md (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
Md Anderson Cancer Center· Houston, TX

Related Studies